Shares of Regenxbio Inc. (NASDAQ:RGNX) have been assigned an average broker rating score of 1.13 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Analysts have set a 1 year consensus price target of $30.50 for the company and are forecasting that the company will post ($0.60) EPS for the current quarter, according to Zacks. Zacks has also given Regenxbio an industry rank of 86 out of 265 based on the ratings given to related companies.
A number of analysts have weighed in on the stock. Piper Jaffray Cos. set a $25.00 target price on shares of Regenxbio and gave the stock a “buy” rating in a report on Thursday, August 18th. Zacks Investment Research cut shares of Regenxbio from a “buy” rating to a “hold” rating in a report on Thursday, July 7th. Finally, Chardan Capital reissued a “buy” rating on shares of Regenxbio in a report on Monday, August 22nd.
Shares of Regenxbio (NASDAQ:RGNX) opened at 14.59 on Tuesday. The firm’s market cap is $386.12 million. The company has a 50 day moving average of $12.68 and a 200 day moving average of $11.00. Regenxbio has a 52 week low of $7.07 and a 52 week high of $25.90.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. On average, equities research analysts anticipate that Regenxbio will post ($2.37) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in RGNX. BlackRock Investment Management LLC raised its position in Regenxbio by 227.7% in the second quarter. BlackRock Investment Management LLC now owns 83,889 shares of the company’s stock valued at $671,000 after buying an additional 58,288 shares in the last quarter. BlackRock Advisors LLC raised its position in shares of Regenxbio by 27,318.5% in the second quarter. BlackRock Advisors LLC now owns 687,657 shares of the company’s stock worth $5,501,000 after buying an additional 685,149 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Regenxbio by 116.4% in the second quarter. Vanguard Group Inc. now owns 569,935 shares of the company’s stock worth $4,559,000 after buying an additional 306,596 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Regenxbio by 196.1% in the second quarter. Nationwide Fund Advisors now owns 12,815 shares of the company’s stock worth $103,000 after buying an additional 8,487 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Regenxbio by 173.3% in the second quarter. California State Teachers Retirement System now owns 42,475 shares of the company’s stock worth $340,000 after buying an additional 26,935 shares in the last quarter. Institutional investors and hedge funds own 68.73% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.